同位素2011，Vol.24Issue(3)：177-181,5.
新型多肽示踪剂131I-RRL肿瘤分子显像研究
Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging
摘要
Abstract
To study the potential application value of Ary-Ary-Leu(RRL) specially combined with tumor derived endothelial cells in tumor molecular imaging for melanoma bearing mice, a novel peptide RRL was designed and labeled with 131I by chloramine-T method, and mice bearing melanoma tumor were injected 131I-RRL to imaging. The labeling results showed that the optimized condition were following: 50 μg RRL, 10 μL(74 MBq)Na131 I, 90 μg chloramine-T, total reaction volume 100 μL, and reaction time 3 min, the labeling yield was over 69%. The labeling compound was purified by Sephadex G25, its radiochemical purity was >95%. In vitro binding experiments, FITC-RRL was mainly combine with tumor cells and tumor angiogenesis endothelial cells, and in the SPECT imaging, 131I-RRL peptide could successfully image the tumor in nude mice bearing melanoma tumor for 24 h after in- jection. The results indicated that small molecular peptide RRL was a promising carrier fortumor molecular imaging and radioimmunotherapy.关键词
131I标记/RRL多肽/肿瘤/分子显像Key words
13II labeling/ peptide RRL/ tumor/ molecular imaging分类
医药卫生引用本文复制引用
卢霞,王荣福,张春丽..新型多肽示踪剂131I-RRL肿瘤分子显像研究[J].同位素,2011,24(3):177-181,5.基金项目
国家自然科学基金(30870729) （30870729）
国家重点基础研究发展计划基金-973计划(2006CB705705) （2006CB705705）
北京大学985Ⅱ期基金资助(985-2-056) （985-2-056）
